Kumbaya moments aren’t easy to come by in most pharmaceutical litigation.
But with a May bench trial postponed due to COVID-19 concerns, drug companies litigating the validity of patents on a diabetes treatment have jointly agreed to extend the Hatch-Waxman Act’s automatic stay against launching a generic product.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]